Cytotoxic activity of SAR442085, daratumumab and isatuximab against the indicated MM cell lines in the presence of total PBMCs, purified NK cells, and monocyte-derived macrophages from healthy donors
| Target cells . | Effector cells . | Compound . | Geometric mean EC50rel (pM) [95% CI]* . | Fold improvement† . |
|---|---|---|---|---|
| RPMI 8226 | HD PBMC | SAR442085 | 54.63 [35.7 ; 83.7] | 3 |
| Daratumumab | 182.9 [76.82 ; 735.6] | |||
| Isatuximab | 130.8 [72.37 ; 236.3] | |||
| KMS-12-BM | HD PBMC | SAR442085 | 14.78 [7.33 ; 29.79] | 5 |
| Daratumumab | 73.44 [36.9 ; 146.1] | |||
| Isatuximab | 69.2 [32.79 ; 146.4] | |||
| RPMI 8226 | HD NK | SAR442085 | 1.07 [0.08 ; 14.49] | 10 |
| Daratumumab | 10.83 [5.68 ; 20.64] | |||
| Isatuximab | 11.64 [4.11 ; 32.98] | |||
| MOLP8 | HD monocyte-derived macrophages | SAR442085 | 18.35 [12.72 ; 26.45] | 4 |
| Daratumumab | 66.33 [20.6 ; 213.3] | |||
| Isatuximab | 55.51 [17.38 ; 177.3] |
| Target cells . | Effector cells . | Compound . | Geometric mean EC50rel (pM) [95% CI]* . | Fold improvement† . |
|---|---|---|---|---|
| RPMI 8226 | HD PBMC | SAR442085 | 54.63 [35.7 ; 83.7] | 3 |
| Daratumumab | 182.9 [76.82 ; 735.6] | |||
| Isatuximab | 130.8 [72.37 ; 236.3] | |||
| KMS-12-BM | HD PBMC | SAR442085 | 14.78 [7.33 ; 29.79] | 5 |
| Daratumumab | 73.44 [36.9 ; 146.1] | |||
| Isatuximab | 69.2 [32.79 ; 146.4] | |||
| RPMI 8226 | HD NK | SAR442085 | 1.07 [0.08 ; 14.49] | 10 |
| Daratumumab | 10.83 [5.68 ; 20.64] | |||
| Isatuximab | 11.64 [4.11 ; 32.98] | |||
| MOLP8 | HD monocyte-derived macrophages | SAR442085 | 18.35 [12.72 ; 26.45] | 4 |
| Daratumumab | 66.33 [20.6 ; 213.3] | |||
| Isatuximab | 55.51 [17.38 ; 177.3] |